Clinical trials: Lennox Gastaut Syndrome
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex
The goal of this clinical trial is to learn the best way to switch children with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) taking 'artisanal' (non pharmaceutical-grade) cannabidiol (CBD) to Epidiolex for treatment of…
- Trial name
- CANN-SWITCH (NCT06924827)
- Testing
- Epidiolex 100 mg/mL Oral Solution
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Elizabeth Donner
Epilepsy, Dravet Syndrome
Turmeric as Treatment in Epilepsy
This is a single center open-label pilot clinical trial of patients 1-70 years of age with greater than 6 seizures per month diagnosed with Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis, or focal seizures.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis
- Trial name
- NCT03254680
- Testing
- Turmeric
- Where
- United States
- Sponsor
- NYU Langone Health
Dravet Syndrome, Lennox Gastaut Syndrome
Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome
The clinical trial "A Prospective Single-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol (CBD-OS®) on Dravet syndrome and Lennox-Gastaut Syndrome" is a single-group phase III study done in single tertiary…
- Trial name
- NCT04611438
- Testing
- Cannabidiol
- Where
- South Korea
- Volunteers
- 107 people
- Sponsor
- Yonsei University
Dravet Syndrome, Lennox Gastaut Syndrome
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome, Lennox-Gastaut syndrome or epileptic encephalopathy
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy
- Trial name
- NCT03936777
- Testing
- ZX008 (Fenfluramine Hydrochloride)
- Where
- 71 sites in United States, Australia and 12 more
- Volunteers
- 412 people
- Sponsor
- Zogenix, Inc.
Seizures
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
This is a multicenter, open-label trial to assess the long-term safety and efficacy of Cannabidiol Oral Solution as adjunctive therapy for pediatric participants with treatment-resistant seizure disorders, including…
- Trial name
- NCT02318602
- Testing
- Cannabidiol Oral Solution
- Where
- 11 sites in United States
- Volunteers
- 52 people
- Sponsor
- INSYS Therapeutics Inc
Lennox-Gastaut Syndrome
Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
This study is being conducted to evaluate the effects of GWP42003-P on cognition in pediatric participants, aged 3 to 10 years, with Lennox-Gastaut Syndrome (LGS).
- Trial name
- EPI-COG (NCT04133480)
- Testing
- GWP42003-P
- Sponsor
- Jazz Pharmaceuticals
Epileptic Encephalopathy
Cannabidiol in Children With Refractory Epileptic Encephalopathy
This study will assess the safety and tolerability of a cannabidiol-enriched Cannabis Herbal Extract in a small group of children with refractory epileptic encephalopathy.
- Trial name
- CARE-E (NCT03024827)
- Testing
- CanniMed® 1:20
- Where
- 4 sites in Canada
- Volunteers
- 20 people
- Sponsor
- University of Saskatchewan
Lennox Gastaut Syndrome (LGS)
A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome
The aims of the study are: to learn if soticlestat, when given as add-on therapy, reduces the number of major motor drop seizures in children, teenagers, and adults with Lennox-Gastaut Syndrome.
- Trial name
- NCT04938427
- Testing
- Soticlestat
- Where
- 98 sites in United States, Australia and 16 more
- Volunteers
- 270 people
- Sponsor
- Takeda
Epilepsy, Lennox Gastaut Syndrome
Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy
In this trial, the potential anti-epileptic effect of low dose fenfluramine in Lennox Gastaut epilepsy will be studied. An exploratory dose finding add-on trial is proposed.
- Trial name
- FFA-LGS (NCT02655198)
- Testing
- Fenfluramine
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- KU Leuven
Lennox Gastaut Syndrome
Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
This is an open-label, multi-center study of carisbamate in adult and pediatric subjects with LGS, with single- and multiple-dose PK assessments from Days 1 through 73.
- Trial name
- NCT03731715
- Testing
- Carisbamate
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- SK Life Science, Inc.
Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS)
CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome
This study is a preliminary open-label, single-arm Phase II investigation into the safety and efficacy of transdermal cannabidiol (CBD) delivered using GT4 skin bream technology in individuals diagnosed with Dravet and/or…
- Trial name
- NCT06738732
- Testing
- CBD: GT4 Transdermal Delivery System
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Alexander Rotenberg
Lennox Gastaut Syndrome
Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).
- Trial name
- NCT04062981
- Testing
- Carisbamate
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- SK Life Science, Inc.
Generalized Epilepsy, Infantile Spasms
Metabolic Abnormalities in Children With Epilepsy
This study is designed to use positron emission tomography to measure brain energy use. Positron Emission Tomography (PET) is a technique used to investigate the functional activity of the brain.
- Conditions
- Generalized Epilepsy, Infantile Spasms, Metabolic Disease, Partial Epilepsy
- Trial name
- NCT00001325
- Testing
- 18 FDG
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Dravet Syndrome, Lennox Gastaut Syndrome
The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy
The purpose of this study is to determine if cannabidiol (CBD) obtained via the state of Minnesota reduces seizures in patients with severe intractable epilepsy (Dravet Syndrome or Lennox Gastaut Syndrome), and to measure blood…
- Trial name
- NCT02910297
- Sponsor
- Gillette Children's Specialty Healthcare
Lennox-Gastaut Syndrome
A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS
This is a Phase 3b/Phase 4 study. The purpose of this study is to learn more about the efficacy of using CBD-OS as an add-on therapy for the treatment of LGS in adults.
- Trial name
- EpiGOAL (NCT07728097)
- Testing
- Cannabidiol Oral Solution
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jazz Pharmaceuticals
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
This study will be conducted to evaluate the safety, pharmacokinetics (PK), and efficacy of adjunctive GWP42003-P in participants < 2 years of age with tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome (LGS), or Dravet…
- Conditions
- Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
- Trial name
- NCT04485104
- Testing
- GWP42003-P
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 3 people
- Sponsor
- Jazz Pharmaceuticals
Lennox-Gastaut Syndrome
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.
- Trial name
- NCT01151540
- Testing
- Rufinamide
- Where
- 23 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Eisai Co., Ltd.
Lennox-Gastaut Syndrome
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
This surveillance's objectives are 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Efficacy during long-term administration 4. Factors considered to have effect to safety and effectiveness 5.
- Trial name
- NCT02175173
- Testing
- Rufinamide
- Where
- 2 sites in Japan
- Volunteers
- 707 people
- Sponsor
- Eisai Co., Ltd.
Lennox Gastaut Syndrome (LGS)
The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial
The CADET Trial will investigate the effectiveness of deep brain stimulation (DBS) to reduce the frequency of seizures in children with Lennox-Gastaut syndrome (LGS).
- Trial name
- CADET (NCT06924086)
- Testing
- Deep Brain Stimulation
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- University College, London
Epilepsy, Seizures
Ketogenic Diet for Child Epilepsy and Seizure Control
Twenty to thirty percent of children with epilepsy continue to suffer from seizures, even when treated with currently available anticonvulsant medications.
- Conditions
- Epilepsy, Seizures, Lennox-Gastaut Syndrome
- Trial name
- NCT00004729
- Testing
- Ketogenic diet
- Where
- United States
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)